Tanshinone IIA suppresses inflammatory bone loss by inhibiting the synthesis of prostaglandin E2 in osteoblasts

European Journal of Pharmacology

Volumn 601, Issue 1-3, 2008, Pages 30-37

  Kwak, Han Bok ^a   Sun, Hyun Min ^b   Ha, Hyunil ^b   Kim, Ha Neui ^b   Lee, Jong Ho ^b   Kim, Hong Hee ^b   Shin, Hong In ^c   Lee, Zang Hee ^b  

^a Wonkwang University   (South Korea)

^b School of Dentistry   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

LPS; Osteoclast; Prostaglandin E2; RANKL; Tanshinone IIA

Indexed keywords

CYCLOOXYGENASE 2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2; TANSHINONE IIA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; BONE MARROW CELL; CALVARIA; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; INFLAMMATION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE DISEASES; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MICE; MICE, INBRED ICR; OSTEOBLASTS; OSTEOCLASTS; PHENANTHRENES;

EID: 56949086318     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.034     Document Type: Article

References (39)

1. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., and Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9 (1998) 143-150
2. Aderem A., and Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 406 (2000) 782-787
3. Boyle W.J., Slimonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
4. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., and Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283 (1980) 666-668
5. Cui L., Wu T., Liu Y.Y., Deng Y.F., Ai C.M., and Chen H.Q. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacol. Sin. 25 (2004) 678-684
6. Everts B., Wahrborg P., and Hedner T. COX-2-specific inhibitors: the emergence of a new class of analgesic and anti-inflammatory drugs. Clin. Rheumatol. 19 (2000) 331-343
7. Fu J.Y., Masferrer J.L., Seibert K., Raz A., and Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265 (1990) 16737-16740
8. Galibert L., Tometsko M.E., Anderson D.M., Cosman D., and Dougall W.C. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J. Biol. Chem. 273 (1998) 34120-34127
9. Gregory L.S., Kelly W.L., Reid R.C., Fairlie D.P., and Forwood M.R. Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats. Bone 39 (2006) 134-142
10. Ha H., Lee J.H., Kim H.N., Kim H.M., Kwak H.B., Lee S., Kim H.H., and Lee Z.H. α-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J. Immunol. 176 (2006) 111-117
11. Inada M., Matsumoto C., Uematsu S., Akira S., and Miyaura C. Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblasts plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation. J. Immunol. 177 (2006) 1879-1885
12. Jang S.I., Jeong S.I., Kim K.J., Kim H.J., Yu H.H., Park R., Kim H.M., and You Y.O. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1 beta and IL-6 in activated RAW 264.7 cells. Planta Med. 69 (2003) 1057-1059
13. Kim H.H., Kim J.H., Kwak H.B., Huang H., Han S.H., Ha H., Lee S.W., Woo E.R., and Lee Z.H. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge. Biochem. Pharmacol. 67 (2004) 1647-1656
14. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., Iwata T., Ohnishi H., Matozaki T., Kodama T., Taniguchi T., Takayanagi H., and Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428 (2004) 758-763
15. Kwak H.B., Yang D., Ha H., Lee J.H., Kim H.N., Woo E.R., Lee S., Kim H.H., and Lee Z.H. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1. Exp. Mol. Med. 38 (2006) 256-264
16. Lader C.S., and Flanagan A.M. Prostaglandin E2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro. Endocrinology 139 (1998) 3157-3164
17. Liu Y.Z., Dvornyk V., Lu Y., Shen H., Lappe J.M., Recker R.R., and Deng H.W. A novel pathophysiological mechanism for osteoporosis suggested by an in vivo gene expression study of circulating monocytes. J. Biol. Chem. 280 (2005) 29011-29016
18. Lomaga M.A., Weh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., Morony S., Capparelli C., Van G., Kaufman S., van der Heiden A., Itie A., Wakeham A., Khoo W., Sasaki T., Cao Z., Penninger J.M., Paige C.J., Lacey D.L., Dunstan C.R., Boyle W.J., Goeddel D.V., and Mak T.W. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13 (1999) 1015-1024
19. McCoy J.M., Wicks J.R., and Audoly L.P. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110 (2002) 651-658
20. Miyaura C., Inada M., Matsumoto C., Ohshiba T., Uozumi N., Shimizu T., and Ito A. An essential role of cytosolic phospholipase A2α in prostaglandin E2-mediated bone resorption associated with inflammation. J. Exp. Med. 197 (2003) 1303-1310
21. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors structures, properties, and functions. Physiol. Rev. 79 (1999) 1193-1226
22. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
23. Portanova J.P., Zhang Y., Anderson G.D., Hauser S.D., Masferrer J.L., Seibert K., Gregory S.A., and Isakson P.C. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med. 184 (1996) 883-891
24. Sato N., Takahashi N., Suda K., Nakamura M., Yamaki M., Ninomiya T., Kobayashi Y., Takada H., Shibata K., Yamamoto M., Takeda K., Akira S., Noguchi T., and Udagawa N. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J. Exp. Med. 200 (2004) 601-611
25. Shao J., Mark Evers B., and Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J. Biol. Chem. 279 (2004) 14287-14293
26. Siegle I., Klein T., Backman J.T., Saal J.G., Nusing R.M., and Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum. 41 (1998) 122-129
27. Suda K., Udagawa N., Sato N., Takami M., Itoh K., Woo J.T., Takahashi N., and Nagai K. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 172 (2004) 2504-2510
28. Suzawa T., Miyaura C., Inada M., Maruyama T., Sugimoto Y., Ushikubi F., Ichikawa A., Narumiya S., and Suda T. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141 (2000) 1554-1559
29. Takahashi K., Ouyang X., Komatsu K., Nakamura N., Hattori M., Baba A., and Azuma J. Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells. Biochem. Pharmacol. 64 (2002) 745-749
30. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83 (2005) 170-179
31. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7 (2007) 292-304
32. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., Kodama T., and Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3 (2002) 889-901
33. Tang F., Wu X., Wang T., Wang P., Li R., Zhang H., Gao J., Chen S., Bao L., Huang H., and Liu P. Tanshinone IIA attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul. Pharmacol. 46 (2007) 427-438
34. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
35. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 3 (2003) 638-649
36. Wang X., Wei Y., Yuan S., Liu G., Lu Y., Zhang J., and Wang W. Potential anticancer activity of tanshinone IIA against human breast cancer. Int. J. Cancer 116 (2005) 799-807
37. Wang X., Morris-Natschke S.L., and Lee K.H. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med. Res. Rev. 27 (2007) 133-148
38. Yang L., Zou X., Liang Q., Chen H., Feng J., Yan L., Wang Z., Zhou D., Li S., Yao S., and Zheng Z. Sodium tanshinone IIA sulfonate depresses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway. Exp. Mol. Med. 39 (2007) 65-73
39. Zou W., and Bar-Shavit Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J. Bone Miner. Res. 7 (2002) 1211-1218